JW CreaGene is New paradigm

Cancer is one of the key causes of death throughout the world and its survival rate is reported to be very low. In most cases, recurrence that follows the primary treatment, systemic metastasis or existence of minute residual cancer, which is difficult to detect at the time of the primary treatment, or metastasized cancer at early stage have been reported to be the key causes of death arising from cancer.

JW CreaGene holds the rights for the dendritic cell technology used in development of cancer treatment and drug delivery technology (CTP: Cytoplasmic Transduction Peptide) that can effectively deliver polymer substances to the cells as the key foundation technologies. Moreover, the company is developing dendritic cell therapeutics aimed at enhancing immunity and immune tolerance by applying the relevant technologies.